Figure 3.
Figure 3. Survival curves of PCNSL with disease responsive to MATRix chemoimmunotherapy. PFS (A) and OS (B) curves of PCNSL patients with disease responsive to a MATRix regimen and consolidated with WBRT (dotted lines) or HDC/ASCT (continuous lines) in the IELSG32 trial.37

Survival curves of PCNSL with disease responsive to MATRix chemoimmunotherapy. PFS (A) and OS (B) curves of PCNSL patients with disease responsive to a MATRix regimen and consolidated with WBRT (dotted lines) or HDC/ASCT (continuous lines) in the IELSG32 trial.37 

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal